CHI3L2 and glioblastoma: Moreover, GBM patients with a high expression of CHI3L2 had a poor overall survival (Figure 5(a), p = 0.0077, HR (95%CI) = 1.61(1.12 − 2.33)), prognosis-free survival (Figure 5(b), p = 0.0063, HR (95%CI) = 1.64(1.14 − 2.37)), and disease-specific survival (Figure 5(c), p = 0.022, HR (95%CI) = 1.58(1.07 − 2.35)) with a 3-year AUC of 0.664 (Figure 5(a)), 0.678 (Figure 5(b)), and 0.698 (Figure 5(c)), respectively.